Tagged with B

Roundup Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access developments.   Coronavirus leading to ICU drug shortages In the UK the coronavirus pandemic is leading to shortages of drugs…

Pharma Faces Mouloud Boukhachab, Pierre Fabre’s managing director for Africa, the Middle East and Turkey, took on the new responsibilities of his current position in March 2020 at the beginning of the coronavirus pandemic. In a recent interview with PharmaBoardroom, Boukhachab outlined the career trajectory that has led him to his current…

Coronavirus IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of collaboration being demonstrated as key industry players work towards a common goal.*   Last week, high-level representatives from seven companies…

Mexico UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region carries for the firm.   The upcoming three years are crucial and UCB Mexico wants to play a role elevating…

USA Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global experiences in innovative biopharma and biosimilars are informing her leadership strategy in the US generics space. Lynch also outlines how greater uptake of biosimilar medicines can be fostered…

China Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but challenging domestic Chinese market.   I-Mab: Observing Competitors and Staying Flexible I-Mab already has a fairly advanced China portfolio, with…

Korea Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing clinical trials, and the complementarity of oncolytic virus with other gene therapies such as CAR-T.   Oncolytic virus is not…

Belgium Marijke Eyssen of the Belgian Health Care Knowledge Centre (KCE) introduces the institution’s mission, core values, how it chooses areas of research, and the crucial work the KCE does in non-industry clinical trials.   High scientific quality is also really important to us, as well as transparency in our reporting.…

China PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019, his commercial expectations for their flagship PD-1/PD-L1 product, and the impact of COVID-19 on their operations.   The core business…

UAE Working non-stop to catch up with its footprint in other regions, Boston Scientific is investing heavily in the MENA markets. Tarek El Rahbani, managing director for the region, shares the company’s change in strategy, opting to have enhanced direct presence in the region. Moreover, he explains why Boston Scientific’s therapies…

Belgium Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company was acquired by Johnson & Johnson. Sonja Willems, managing director of Janssen Benelux, discusses the company’s response to the COVID-19…

USA Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent attraction, and navigating the COVID-19 crisis.   The US is the largest generics market in the world, so it is an absolutely key market for Sandoz, representing around 26…